

Eric L. Saunders

Counsel, Gemini Law LLP



 esaunders@geminilaw.com

LANGUAGE

- English
- German

BAR ADMISSIONS

- New York
- District of Columbia

EDUCATION

- J.D., The George Washington University Law School, with High Honors, Order of the Coif, 2017
- M.A., University of Central Arkansas, 2012
- B.A., Hendrix College, *summa cum laude*, 2003

AWARDS / HONORS

- Empire State Counsel 2019 – Awarded for outstanding service to pro bono clients
- George Washington Scholar – Awarded to the top 15% of law school class
- Associate Editor – The George Washington Law Review
- Executive Committee Member – The George Washington Moot Court Board

Eric L. Saunders is a Counsel at Gemini Law. Eric has extensive experience in patent litigation, including Hatch-Waxman, BPCIA, and medical device patent litigation, Patent Trial and Appeal Board proceedings, including *inter partes* review, pre-litigation strategy and advice. Eric is admitted to practice in both New York and the District of Columbia.

Eric spent the first years of his legal career as an IP Litigation associate at Willkie Farr & Gallagher LLP in New York and Washington, D.C., gaining valuable experience in Hatch-Waxman litigation, including two District Court trials, as well as working on the first ever BPCIA case to go to a jury trial. Eric's trial court experience extends beyond life sciences, including jury trial experience involving software patents and pre-trial litigation across a wide variety of technical fields, including medical devices, software, and patent-related antitrust issues.

Beyond patent litigation, Eric also has extensive experience in trademark strategy, prosecution, and enforcement. He has also advised clients regarding copyright strategy and registration. In addition to his litigation experience, Eric has advised clients on numerous major transactions, with a particular focus on intellectual property risk management and transfers of IP rights and obligations.

Eric earned his undergraduate degree from Hendrix College and a master's degree from the University of Central Arkansas. Eric received his Juris Doctorate, with High Honors, from the George Washington University School of Law, and was inducted into the Order of the Coif. At George Washington, Eric was a member of the executive committee of the Moot Court Board, the editorial staff of the George Washington University Law Review, the American Intellectual Property Law Association, and the Space Law Club.

EXPERIENCE

- Representing Celltrion in BPCIA proceedings relating to EYLEA (afibercept).
- Represented Celltrion in BPCIA litigation relating to PROLIA/XGEVA (denosumab).
- Successfully represented Hospira/Pfizer in Hatch-Waxman patent litigation involving epinephrine injectable products marketed by Belcher Pharmaceuticals. This case was tried before then-Chief Judge Leonard P. Stark (now on the Federal Circuit).
- Represented Hospira/Pfizer in Hatch-Waxman patent litigation involving epinephrine injectable products marketed by Par Pharmaceuticals, in both the District of Delaware and the Federal Circuit.
- Represented Hospira/Pfizer in the Federal Circuit appeal of the first litigation under the BPCIA to be tried to a jury.
- Represented Pfizer in patent litigation relating to the COVID-19 vaccine.
- Represented La Jolla Pharmaceuticals in Hatch-Waxman patent litigation involving Angiotensin II products.
- Represented Insulet Corporation in medical device patent litigation against Roche regarding wearable insulin pumps.
- Represented Accord BioPharma in *inter partes* review proceedings at the Patent Trial and Appeals Board successfully challenging opioid patents.
- Represented Netflix, Inc. in patent litigation brought by a patent assertion entity regarding streaming software, which resulted in a successful jury trial in the Central District of California.
- Represented Johnson Controls in patent litigation relating to digital twin building management software patents.
- Represented LG Electronics in *inter partes* review proceedings at the Patent Trial and Appeals Board challenging wireless device patents.

PUBLICATIONS

- The Bio-Quarterly: Willkie's Biologics and Biosimilars Newsletter, February 2021
- The Bio-Quarterly: Willkie's Biologics and Biosimilars Newsletter, November 2020
- The Bio-Quarterly: Willkie's Biologics and Biosimilars Newsletter, July 2020
- The Bio-Quarterly: Willkie's Biologics and Biosimilars Newsletter, April 2020
- The Bio-Quarterly: Willkie's Biologics and Biosimilars Newsletter, January 2020
- The Bio-Quarterly: Willkie's Biologics and Biosimilars Newsletter, October 2019
- The Bio-Quarterly: Willkie's Biologics and Biosimilars Newsletter, July 2019
- The Bio-Quarterly: Willkie's Biologics and Biosimilars Newsletter, April 2019
- The Bio-Quarterly: Willkie's Biologics and Biosimilars Newsletter, October 2018
- The Bio-Quarterly: Willkie's Biologics and Biosimilars Newsletter, July 2018